You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Improved Treatment of Colorectal Cancer with CF10
SBC: Deep Creek Pharma, LLC Topic: 102PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CN-105 Improves Functional Outcome After Intracranial Hemorrhage
SBC: AegisCN LLC Topic: 106Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
ARRAY: A novel polymeric mesh for prophylactic antibiotic protection of cardiac implantable electronic devices
SBC: 21MedTech LLC Topic: NHLBIPROJECT SUMMARY 21MedTech, LLC is developing the ARRAYTM antibiotic-loaded envelope to address the need for novel methods to tackle rising rates of infections associated with cardiovascular implantable electronic devices (CIEDs). There were 1.5 million CIEDs implanted in 2011 and that number continues to grow. Between 1% and 4% of implantations result in infection, which have potential for severe ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel recombinant sensors to study histone ubiquitin signaling
SBC: Epicypher, Inc. Topic: 400PROJECT SUMMARYMonoubiquitination (Ub) of histones is an important post-translational modification (PTM) that regulates multiple DNA-related processes including DNA replication, transcription, and repair. Aberrant regulation of histone Ub is strongly linked to the pathogenesis of diverse diseases, including cancer, aging, and inflammation. However, the ability to map the distribution and dynamics ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of ultra-efficient antibodies for single cell mapping applications
SBC: Epicypher, Inc. Topic: NIAIDPROJECT SUMMARYHistone post-translational modifications (PTMs) are some of the most widely studied epigenomic factors, and alterations in histone PTM abundance / distribution have been implicated in numerous disease etiologies. Epigenomic mapping of histone PTMs in limited cell populations or single cells (SCs) would provide the opportunity to study the epigenetic landscape of rare and heterogenou ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial-Targeted Therapy for Macular Degeneration
SBC: ECLIPSE LIFE SCIENCES, INC. Topic: 100SUMMARY Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. Most AMD cases are the nonexudative (or “dry”) form, which affects up to 200 million patients globally and is comprised of intermediate dry AMD, characterized by formation of sub-retinal pigment epithelium (RPE) deposits called drusen, and geographic atrophy (GA), more advanced disease characte ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Multiomic genomic mapping with long read sequencing
SBC: Epicypher, Inc. Topic: 400PROJECT SUMMARYGenomic mapping of histone post-translational modifications (PTMs), chromatin-associated proteins (CAPs), and DNA methylation (DNAme) is a powerful approach for biomedical research and drug development. Current genomics assays (e.g. ChIP-seq, CUTandRUN) rely on second generation short-read sequencing (SRS), wherein short reads (lt500bp) limit the ability to a) analyze concordance of ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercializing CivaSheet for Pancreatic Cancer Patients
SBC: CIVATECH ONCOLOGY INC Topic: NCICivaTech Oncology’s mission is to provide improved radiation therapy directly to diseased tissues while sparing healthy tissues. With NIH/NCI SBIR support, the Company has eliminated local recurrence of disease in pancreatic cancer patients – a huge success. Pancreatic cancer is predicted to soon become the most commonly diagnosed cancer in the US and there are no significant, impactful therap ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959
SBC: T3D Therapeutics, Inc. Topic: NIAT3D-959 is a new chemical entity, orally delivered, small molecule, dual nuclear receptor agonist aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD), it is non- amyloid/non-tau-directed. Metabolic homeostasis, inherently altered in AD, leads to protein misfolding resulting in plaque formation, tangle formation and inflammation. Exploratory huma ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Mutational profiling in human cells as an in vitro alternative to in vivo mutagenicity assessments
SBC: ScitoVation, LLC Topic: RPROJECT SUMMARY Mutations are heritable changes in the cellular genome and are key events in the induction of cancer, birth defects, and neurological diseases. The lack of a mutagenicity bioassay in human cells is a major data gap in the genetic toxicology test battery used by regulatory agencies for hazard identification and quantitative risk assessments. ScitoVation is developing a New Approach ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health